
    
      This is a phase II study of BIBW 2992 (Afatinib) in patients with hormone and chemotherapy
      (docetaxel) refractory, HER2 overexpressing prostate cancer. The exploratory study following
      a two stage Gehan design. In the first stage 29 patients with be treated. Additional patients
      will be recruited in a second stage depending on the number of responding patients in the
      first step. Patients will receive BIBW 2992 (Afatinib) orally at a dose of 50 mg daily.
      Response to therapy will be scored according to PSA values (Bubley criteria) and to CT scans
      (RECIST criteria). Patients will be seen at 2 or 4 weeks intervals by a medical professional
      while on the medication for toxicity assessment and physical examination. Disease evaluations
      will occur at baseline and every 2 months thereafter. These evaluations will include PSA
      testing and CT Scans (if appropriate).
    
  